Table 1.
Baseline clinical characteristics.
| Variables | Overall (n = 144) | No Events (n = 122) | V Events (n = 22) | p |
|---|---|---|---|---|
| Males, n (%) | 123 (85.4) | 102 (84) | 21 (95) | 0.2 |
| Age, median (IQR) | 64 (55–72) | 63 (55–72) | 68 (56–80) | 0.5 |
| Diabetes, n (%) | 67 (46.5) | 57 (47) | 10 (46) | 1 |
| Hypertension, n (%) | 113 (78.5) | 95 (84) | 18 (82) | 0.8 |
| Smoke, n (%) | 74 (51.4) | 64 (53) | 10 (46) | 0.6 |
| Dyslipidemia, n (%) | 101 (70.1) | 83 (68) | 18 (82) | 0.3 |
| Revascularization, n (%) | 77 (53,5%) | 63 (81.8) | 14 (18.2) | <0.001 |
| CKD, n (%) | 44 (30.6) | 35 (29) | 9 (41) | 0.3 |
| AF n (%) | 30 (20.8) | 25 (21) | 5 (23) | 0.8 |
| Pre-EF, % | 30 (28–33) | 30 (28–33) | 30 (30–35) | 1 |
| BBs, n (%) | 98 (72.1) | 84 (73) | 14 (67) | 0.6 |
| ACEIs | 78 (54) | 63 (52) | 15 (68) | 0.4 |
| ARBs | 33 (23) | 30 (25) | 3 (14) | 0.4 |
| Amiodarone, n (%) | 27 (19) | 18 (15) | 9 (41) | 0.013 |
CKD indicates chronic kidney disease; AF indicates atrial fibrillation; pre-EF indicates ejection fraction predevice implant; BBs indicates beta-blockers; BBs indicates Beta blockers; ACEIs indicates angiotensin converting enzyme inhibitors; ARBs indicates Angiotensin II receptor blockers.